# PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Study · id `cardio:ct-nct04142658` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04142658](<https://clinicaltrials.gov/study/NCT04142658>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04142658

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 863 participants.

## Technical summary

Registry record NCT04142658. Randomized; no masking; primary purpose treatment. Start 2020-05-01 (actual); primary completion 2022-12-12 (actual). Results posted on 2024-03-20.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 863 participants (enrolled count; ClinicalTrials.gov record NCT04142658, source copy `cardio:ctgov-nct04142658-2024-03-20`, retrieved 2026-10-26)
- Started: 2020-05-01 (actual) (ClinicalTrials.gov record NCT04142658, source copy `cardio:ctgov-nct04142658-2024-03-20`, retrieved 2026-10-26)
- Primary completion: 2022-12-12 (actual) (ClinicalTrials.gov record NCT04142658, source copy `cardio:ctgov-nct04142658-2024-03-20`, retrieved 2026-10-26)
- Completion: 2022-12-12 (actual) (ClinicalTrials.gov record NCT04142658, source copy `cardio:ctgov-nct04142658-2024-03-20`, retrieved 2026-10-26)
- Results first posted: 2024-03-20 (ClinicalTrials.gov record NCT04142658, source copy `cardio:ctgov-nct04142658-2024-03-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04142658, source copy `cardio:ctgov-nct04142658-2024-03-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04142658-2024-03-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
- Condition: Aortic Valve Disease
- Condition: Aortic Valve Stenosis
- Condition: Aortic Valve Failure
- Intervention (Drug): Apixaban 5 MG
- Intervention (Drug): Apixaban 2.5 MG
- Intervention (Drug): Warfarin
- Intervention (Device): On-X Aortic Mechanical Valve
- Lead sponsor: Artivion Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Duke Clinical Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Artivion Inc. (`cardio:org-artivion-inc`)
- Registry lists this organization as a collaborator: Duke Clinical Research Institute (`cardio:org-duke-clinical-research-institute`)

## Provenance

Content hash: fc9d2978f3c7aee34712b649ef36a50629f50122049d454affd4a2fdb4880d70
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
